This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Plasmodium Falciparum Malaria
and you are
between 15 and 60
years old
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

This is a double-blind, multicentre, randomised, parallel group, dose-finding study of the safety, tolerability and efficacy of a three day regimen of the combination of pyronaridine/artesunate in the ratio 3:1. The primary trial objective is to determine the clinical effective dose of orally administered pyronaridine/artesunate (3:1 weight/weight) ratio, in the treatment of patients with acute, symptomatic, uncomplicated P. falciparum malaria using the PCR-corrected adequate clinical and parasitological response (ACPR) at Day 28 as primary endpoint. Secondary trial objectives are to determine the safety of once daily dosing for 3 days of pyronaridine/artesunate (3:1) combination in male and female patients with uncomplicated P. falciparum malaria and to explore possible ethnic differences in safety or efficacy in South East Asia and Africa

Provided treatments

  • Drug: pyronaridine/artesunate

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01594931. The sponsor of the trial is Medicines for Malaria Venture and it is looking for 477 volunteers for the current phase.
Official trial title:
A Randomised, Multi-Centre, Phase II, Dose-ranging Clinical Study to Assess the Safety and Efficacy of Fixed Dose, Orally Administered Pyronaridine and Artesunate (3:1) in Adult Patients With Acute Uncomplicated Plasmodium Falciparum Malaria